Дипиридамол (Dipyridamole)
Международное непатентованное наименование
Дипиридамол (Dipyridamole)
Торговое наименование
Дипиридамол
Производитель, страна
ВЕРТЕК, Россия; Атолл, Россия; ФП "Оболенское", Россия и др.
Лекарственная форма
таблетки, покрытые пленочной оболочкой, 75 мг и 25 мг
Механизм действия
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin.
Dipyridamole has two known effects, acting via different mechanisms of action:
- Dipyridamole inhibits the phosphodiesterase enzymes that normally break down cAMP (increasing cellular cAMP levels and blocking the platelet aggregation response to ADP) and/or cGMP.
- Dipyridamole inhibits the cellular reuptake of adenosine into platelets, red blood cells, and endothelial cells, leading to increased extracellular concentrations of adenosine.
Публикации COVID-19
, , et al. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. February 29, 2020. DOI: 10.1101/2020.02.27.20027557.
Клинические исследования
1.
Название протокола
Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)
Дата начала и окончания КИ
February 10, 2020 - April 10, 2020
Название организации, проводящей КИ
The First Affiliated Hospital of Guangzhou Medical University
Страны
China
Фаза
IV
Кол-во пациентов
460